Longeveron Inc. (LGVN): Revenue
$1.20M
Year ended 2025-12-31
$1.19M
Trailing 12 months to 2026-06-30
-0.6%
3-year compound annual growth
-26.6%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.20M | -49.9% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $2.39M | +237.4% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $709.0K | -42.0% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $1.22M | -6.4% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $1.31M | -76.8% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $5.63M | n/a | 2022-03-11, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Longeveron Inc. (LGVN) | 2025-12-31 | $1.20M | -49.9% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $1.17M | -92.5% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $1.14M | -34.6% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $1.27M | +161.1% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $1.27M | -5.5% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $1.12M | +42.3% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.36M | +66.1% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $1.38M | -0.3% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $1.03M | n/m |
Compare LGVN, NEUP, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗